News

A new study led by Dr. Mikhail Kosiborod found patients with obesity-related heart failure and diabetes had a significant improvement in symptoms when taking semaglutide.

Saint Luke’s Mid America Heart Institute today announced results from the STEP HFpEF DM trial.

During Heart Month, we are talking about the risks of undiagnosed heart failure and treatment options for those with heart failure.

FOX4 talked to Ted Perez and his heart transplant surgeon, Dr. Russ Davis, about the lifelong Chiefs fan's incredible story.

Saint Luke’s Mid America Heart Institute was the first in Kansas and Missouri, and one of only 27 US institutions, to participate in PULSED AF clinical trial.

As of January 1, 2024, Wright Memorial Hospital entered into a new contract with the emergency medicine physicians providing care in the hospital’s emergency department.

As of January 1, 2024, Hedrick Medical Center entered into new contract with the emergency medicine physicians providing care in the hospital’s emergency department.

A man from Columbia, Missouri, got a new heart and a second chance at life, marking the 1,000th heart transplant at Saint Luke's Mid America Heart Institute.

TCTMD talked to Dr. Paul Chan and Dr. Anezi Uzendu about the new study's findings.

The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.